We hope you all had a wonderful Bicycle Day yesterday 🚲
For those who aren’t familiar, April 19, 1943 marks the world’s first acid trip. Albert Hofmann, the chemist who created LSD, dosed himself with the drug to test its effects before riding his bicycle home from the lab.
The day has since become an unofficial holiday for psychonauts. Be sure to check out the Video of the Week to learn more.
Here’s what’s in store for you in today’s issue:
🍄 Microdosing concert for group healing
🍄 Why GoDaddy billionaire is pushing for psychedelic therapy
🍄 A cure for acid flashbacks
🍄 How you can make a difference in the psychedelic revolution
🍄 And more.
In this episode of the Daily Mushroom podcast, we have Dr. Pam Kryskow, a psychedelic researcher, medical doctor, and the medical lead for ketamine-assisted therapy for the Roots to Thrive program. Pam shares the benefits of psychedelic therapy in group settings and how her hiking “trips” helped her cope with daily trauma experienced in her previous job as a firefighter.
On Saturday, Red Light Holland (TRIP) sponsored a first-of-its-kind microdosing concert to determine best practices for group microdosing services.
Participants attended a preparation session and received a customized dose of psilocybin from a therapist.
They spent the next three hours laying on the ground listening to a live classical music concert before attending an optional integration session.
“Both music and community have healing and connective qualities and we are excited to test the potential benefits of combining microdosing psilocybin truffles in this ground-breaking setting,” says one of the event organizers
Data from the event will be used to guide microdosing regulations Oregon and Washington.
Bob Parsons, founder of GoDaddy, suffered from PTSD after witnessing “grisly combat” in the Vietnam War.
It wasn’t until he went through a multiday therapy treatment with psilocybin, ayahuasca, and LSD that he began to feel like his old self again.
“What I think psychedelics did was a reset. Now, I’m like people who haven’t been in combat to a certain degree,” he believes.
Bob is on a mission to help other veterans battling PTSD. He donated $5M to Mount Sinai’s psychedelic research center to fund MDMA therapy training for healthcare practitioners.
Ninnion Therapeutics, a private Texas-based company, hopes microdosing will help patients recover from strokes.
Ischemic strokes block blood flow to the brain, causing brain cells to die.
Microdosing in combination with occupational therapy may be able to strengthen the remaining brain cells to restore lost functions.
The company recently filed a patent application for the treatment. Since there are no approved drugs for stroke recovery, the formulation may qualify for a Breakthrough Therapy designation, which would speed up the development timeline.
Wesana Health (WESA) may expand the indication of its psilocybin formulation after meeting with the FDA. In addition to treating anxiety related to traumatic brain injury, it could also target depression. A $3M private placement will fund phase Ib/IIa depression study next year.
By denying Canadians access to psilocybin, the government is infringing on patients’ rights. According to TheraPsil, the decision to use psilocybin medically should be made between doctor and patient with no requirement for government approval (just like medical cannabis).
If you believe that access to psilocybin for medical purposes is a right, please help TheraPsil prove this in court by donating to their fundraiser.
You’re all caught up! See you next Wednesday 👋